AR106875A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents
Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncerInfo
- Publication number
- AR106875A1 AR106875A1 ARP160103664A ARP160103664A AR106875A1 AR 106875 A1 AR106875 A1 AR 106875A1 AR P160103664 A ARP160103664 A AR P160103664A AR P160103664 A ARP160103664 A AR P160103664A AR 106875 A1 AR106875 A1 AR 106875A1
- Authority
- AR
- Argentina
- Prior art keywords
- tiadiazol
- compounds
- cancer treatment
- compound
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- -1 6-fluoropyridazin 3-yl Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000009127 Glutaminase Human genes 0.000 abstract 1
- 108010073324 Glutaminase Proteins 0.000 abstract 1
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 abstract 1
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto de vista farmacéutico; Q puede ser piridazin-3-ilo, 6-fluoropiridazin 3-ilo; R¹ puede ser H; R² y R³ pueden ser cada uno independientemente alquilo C₁₋₆, o R² y R³ tomados juntos son -(CH₂)₃-; o R¹ y R² tomados juntos pueden ser -(CH₂)₂- y R³ puede ser -CH₃; R⁴ es halo, -CH₃, -OCH₃, -OCHF₂, -OCF₃, o -CN; y n puede ser 0, 1, ó 2. El compuesto de la fórmula (1) puede inhibir la glutaminasa, por ejemplo, GLS1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260784P | 2015-11-30 | 2015-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106875A1 true AR106875A1 (es) | 2018-02-28 |
Family
ID=57460503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103664A AR106875A1 (es) | 2015-11-30 | 2016-11-30 | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10040789B2 (es) |
| EP (1) | EP3383872B1 (es) |
| JP (1) | JP6821680B2 (es) |
| KR (1) | KR20180083411A (es) |
| CN (1) | CN108349965B (es) |
| AR (1) | AR106875A1 (es) |
| AU (1) | AU2016361834B2 (es) |
| BR (1) | BR112018008330B1 (es) |
| CA (1) | CA3005517C (es) |
| CL (1) | CL2018001409A1 (es) |
| CO (1) | CO2018006930A2 (es) |
| DK (1) | DK3383872T3 (es) |
| DO (1) | DOP2018000135A (es) |
| EA (1) | EA035519B9 (es) |
| ES (1) | ES2796562T3 (es) |
| IL (1) | IL259508A (es) |
| MX (1) | MX2018006483A (es) |
| MY (1) | MY195680A (es) |
| NI (1) | NI201800063A (es) |
| NZ (1) | NZ743699A (es) |
| PE (1) | PE20181522A1 (es) |
| PH (1) | PH12018501133A1 (es) |
| SG (1) | SG11201803808VA (es) |
| SV (1) | SV2018005700A (es) |
| TN (1) | TN2018000118A1 (es) |
| TW (1) | TW201731511A (es) |
| WO (1) | WO2017093301A1 (es) |
| ZA (1) | ZA201804361B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201730188A (zh) | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| WO2020078350A1 (zh) * | 2018-10-16 | 2020-04-23 | 南京明德新药研发有限公司 | 噻二唑衍生物及其作为gls1抑制剂的应用 |
| CN114560855B (zh) * | 2021-03-26 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 环烷基甲酰胺类衍生物、其制备方法及用途 |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2782570T1 (sl) * | 2011-11-21 | 2020-02-28 | Calithera Biosciences Inc. | Heterociklični inhibitorji glutaminaze |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) * | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| AU2015204210B2 (en) | 2014-01-06 | 2019-07-18 | Rhizen Pharmaceuticals Sa | Inhibitors of glutaminase |
| GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201733587A (zh) * | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201730188A (zh) * | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
-
2016
- 2016-11-29 US US15/362,989 patent/US10040789B2/en active Active
- 2016-11-29 TW TW105139334A patent/TW201731511A/zh unknown
- 2016-11-30 EA EA201891239A patent/EA035519B9/ru not_active IP Right Cessation
- 2016-11-30 KR KR1020187017163A patent/KR20180083411A/ko not_active Withdrawn
- 2016-11-30 SG SG11201803808VA patent/SG11201803808VA/en unknown
- 2016-11-30 ES ES16805078T patent/ES2796562T3/es active Active
- 2016-11-30 NZ NZ743699A patent/NZ743699A/en unknown
- 2016-11-30 EP EP16805078.9A patent/EP3383872B1/en active Active
- 2016-11-30 DK DK16805078.9T patent/DK3383872T3/da active
- 2016-11-30 CN CN201680067210.XA patent/CN108349965B/zh active Active
- 2016-11-30 MX MX2018006483A patent/MX2018006483A/es unknown
- 2016-11-30 BR BR112018008330-5A patent/BR112018008330B1/pt active IP Right Grant
- 2016-11-30 MY MYPI2018702070A patent/MY195680A/en unknown
- 2016-11-30 TN TNP/2018/000118A patent/TN2018000118A1/en unknown
- 2016-11-30 CA CA3005517A patent/CA3005517C/en active Active
- 2016-11-30 AU AU2016361834A patent/AU2016361834B2/en active Active
- 2016-11-30 AR ARP160103664A patent/AR106875A1/es unknown
- 2016-11-30 WO PCT/EP2016/079253 patent/WO2017093301A1/en not_active Ceased
- 2016-11-30 JP JP2018527201A patent/JP6821680B2/ja active Active
- 2016-11-30 PE PE2018001012A patent/PE20181522A1/es unknown
-
2018
- 2018-05-22 IL IL259508A patent/IL259508A/en active IP Right Grant
- 2018-05-24 CL CL2018001409A patent/CL2018001409A1/es unknown
- 2018-05-29 DO DO2018000135A patent/DOP2018000135A/es unknown
- 2018-05-29 SV SV2018005700A patent/SV2018005700A/es unknown
- 2018-05-29 PH PH12018501133A patent/PH12018501133A1/en unknown
- 2018-05-29 NI NI201800063A patent/NI201800063A/es unknown
- 2018-06-28 ZA ZA2018/04361A patent/ZA201804361B/en unknown
- 2018-06-29 CO CONC2018/0006930A patent/CO2018006930A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106875A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| MX2023000418A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| MX2018008362A (es) | Derivados de quinolin-2-ona. | |
| EA030204B8 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| MX391999B (es) | Piridinas y su uso en el tratamiento del cáncer. | |
| BR112018075736A2 (pt) | composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1 | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| MX2019009266A (es) | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer. | |
| MX392000B (es) | Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer. | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| CL2018001408A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |